REmote SUpervision to Decrease HospitaLization RaTe. Unified and integrated platform for data collected from devices manufactured by different companies: Design and rationale of the RESULT study
Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński, Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński
Abstract
The number of patients with heart failure implantable cardiac electronic devices (CIEDs) is growing. Hospitalization rate in this group is very high and generates enormous costs. To avoid the need for hospital treatment, optimized monitoring and follow-up is crucial. Remote monitoring (RM) has been widely put into practice in the management of CIEDs but it may be difficult due to the presence of differences in systems provided by device manufacturers and loss of gathered data in case of device reimplantation. Additionally, conclusions derived from studies about usefulness of RM in clinical practice apply to devices coming only from a single company. An integrated monitoring platform allows for more comprehensive data analysis and interpretation. Therefore, the primary objective of Remote Supervision to Decrease Hospitalization Rate (RESULT) study is to evaluate the impact of RM on the clinical status of patients with ICDs or CRT-Ds using an integrated platform. Six hundred consecutive patients with ICDs or CRT-Ds implanted will be prospectively randomized to either a traditional or RM-based follow-up model. The primary clinical endpoint will be a composite of all-cause mortality or hospitalization for cardiovascular reasons within 12 months after randomization. The primary technical endpoint will be to construct and evaluate a unified and integrated platform for the data collected from RM devices manufactured by different companies. This manuscript describes the design and methodology of the prospective, randomized trial designed to determine whether remote monitoring using an integrated platform for different companies is safe, feasible, and efficacious (ClinicalTrials.gov Identifier: NCT02409225).
Keywords: RESULT study; heart failure; integrated platform; remote monitoring.
Conflict of interest statement
None declared.
© 2016 Wiley Periodicals, Inc.
Figures



Source: PubMed
Próximos ensaios clínicos
-
University of TennesseeWoodcock Institute for the Advancement of Neurocognitive Research and Applied...Ainda não está recrutandoHabilidades motoras | Saudável | Função executiva
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLCAinda não está recrutandoCarcinoma Anal de Células Escamosas
-
Universita di VeronaAzienda Ospedaliera Universitaria Integrata VeronaAinda não está recrutandoArtrite reumatoide | Doença articular degenerativa do joelhoItália
-
University of Wisconsin, MadisonAlkermes, Inc.Ainda não está recrutando
-
Virginia Commonwealth UniversityAinda não está recrutandoEdema Cerebral | Necrose de RadiaçãoEstados Unidos
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Icahn School of Medicine at Mount...Ainda não está recrutandoCetamina | fMRI | Depressão - Transtorno Depressivo Maior | rTMS | Depressão resistente ao tratamento (TRD)Estados Unidos
-
Weill Medical College of Cornell UniversityBD2 LLCAinda não está recrutandofMRI | Transtorno Bipolar (DB) | rTMS | Depressão Bipolar 1Estados Unidos
-
Xentria, Inc.Ainda não está recrutando
-
Yale UniversityNational Institute of Mental Health (NIMH)Ainda não está recrutando
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeRecrutamentoFeocromocitoma | Feocromocitoma/Paraganglioma | Feocromocitoma Metastático | Feocromocitoma Maligno | Feocromocitoma e paraganglioma (PPGL)Reino Unido
-
Carl Zeiss Meditec-Dublin CoCeRecrutamentoMembrana Epirretiniana | Doença da Retina | Degeneração macular relacionada à idade seca | Anormalidade Vitreorretiniana | Macular Abnormalities | Intraretinal Hyporeflective Space | Subretinal Hyporeflective Space | IS/OS (Ellipsoid Zone) Disruption | Retinal Pigment Epithelium (RPE) Elevation | Retinal...Estados Unidos
-
Celest Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical UniversityRecrutamentoCLDN18.2 Tumores Sólidos PositivosChina